See what a granted.bio analysis looks like
Two full samples on different topics — a therapeutic modality and a diagnostic modality. This is exactly what your included analysis looks like under a $199 3-month platform pass.
Radioligand Therapy for Prostate Cancer
The oncology modality behind Pluvicto and Lutathera, scoped to prostate cancer. PSMA-targeted radioligands, alpha- vs beta-emitter tradeoffs, dosimetry and combination-therapy positioning across 115 NIH-funded projects and 511 cross-linked clinical trials.
Brain Organoid Electrophysiology
3D neural tissue platforms with functional electrophysiological readout — the intersection of MEA hardware, iPSC-derived assembloids, and disease-modeling applications. 122 NIH-funded projects, 70 organizations, and $129.8M active commitments, viewed through the investor lens.
Get your own 3-month platform pass
$199 · 3 months of platform access + one analysis on any life-sciences topic. Generates in a few minutes.